As reported in Indian media, senior officials from the European Commission and India are expected to meet today in Brussels to hold talks on resuming negotiations on the proposed European Union-India free trade agreement.
Months after it called off talks between chief negotiators of the two sides on free trade agreement (FTA) to protest against the ban on sale of around 700 pharma products of a domestic company, India will meet officials from the European Union (EU) later next month to “take stock of the negotiations” on the long-pending FTA.
The escalation in patent protections is set to occur just as drug prices hit all-time highs in Canada and pharmaceutical investment in research and development sinks to decade-long lows.
Although TPP seems a remote issue, it could have a direct impact on EU consumers.
While the agreement was being negotiated, the US Trade Representative stated that a much-criticized arbitration process included in the TPP would not apply to intellectual property. Turns out, it does apply to IP.
A massive trade pact between 12 Pacific rim countries could limit the availability of affordable medicines, the head of the World Health Organization said
There is a paucity of information on drug prices, revenues and other relative information on the economics of the pharmaceutical market.
Preliminary analysis of the thousands of pages of the main chapters of the TPP text show there are still devils in the detail on medicine monopolies, investor rights to sue governments and copyright monopolies.
Implications of the TPP on the Indian pharma industry might not be entirely clear yet. But there is a need for India to engage in the debate of trade deals and public interest.
Les conséquences des dispositions relatives à la propriété intellectuelle contenues dans l’accord signé entre l’Union Européenne et la Tunisie et leurs conséquences sur la santé publique en Tunisie inquiètent.
So far, the NDA government has been a mute spectator to the US pharma strategy of forcing Indian generics manufacturers to produce only what is required for Indian consumers and abandon the export of cheap drugs to Africa
The United States International Trade Commission (USITC) has published a report on IPR policy transparency by India’s new government
Writing pharmaceutical regulations into international trade deals can have costly consequences.
A quick analysis of the leaked text shows there are good reasons to be concerned that the TPP’s generous IP protections could still prove a minefield for efforts to control drug costs in Canada
Ahead of a meeting between Indian Prime Minister Modi and German Chancellor Merkel this week, European manufacturers had already protested India’s patents policy, arguing that it doesn’t protect sensitive technology.
The TPP’s intellectual property chapter represents nothing less than a disaster for global health. Many harmful provisions still remain in the final chapter, bearing out the concerns of public health advocates.
The TPP could give pharmaceutical corporations more power to control medicine markets and “impose higher prices for longer.”
The lack of access to details in the text means governments can put a positive spin on the deal, but the devil is in the detail.
Australia — along with others such as New Zealand and Chile — has been unwilling to offer more than five years protection for the medicines, because longer terms would increase the cost of state-subsidised medical programs.
Countries in the trade bloc would have an alternative of either providing eight years of exclusivity to biologic drugs, or providing five years of so-called data exclusivity plus up to three more years under a regulatory framework in the TPP.